Phase 2 Bone Marrow Clinical Trials
28 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 28 trials
Recruiting
Phase 2
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Acute Myeloid LeukemiaMyelodysplastic SyndromeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+11 more
M.D. Anderson Cancer Center508 enrolled1 locationNCT02115295
Recruiting
Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Acute Lymphoblastic LeukemiaAcute LeukemiaMyeloproliferative Neoplasm+14 more
Fred Hutchinson Cancer Center68 enrolled10 locationsNCT03779854
Recruiting
Phase 2
Low-Dose ATG/PTCy Plus Ivarmacitinib for aGVHD Prevention in Haplo-PBSCT From Parous Female Donors
Graft-Versus-Host-Disease (GVHD)Bone Marrow Transplantation
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine82 enrolled1 locationNCT07570745
Recruiting
Phase 1Phase 2
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRefractory Myelodysplastic Syndrome+4 more
M.D. Anderson Cancer Center52 enrolled1 locationNCT04128748
Recruiting
Phase 1Phase 2
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
LeukemiaInborn Errors of MetabolismHLH+11 more
Children's Hospital of Philadelphia100 enrolled1 locationNCT06839456
Recruiting
Phase 1Phase 2
Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction
Refractory Acute Myeloid LeukemiaBlasts More Than 5 Percent of Bone Marrow Nucleated CellsPersistent Disease
Ohio State University Comprehensive Cancer Center28 enrolled2 locationsNCT04049539
Recruiting
Phase 1Phase 2
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
HemoglobinopathiesMetabolic DisordersHematologic, Immune, or Bone Marrow Disorders+1 more
Washington University School of Medicine220 enrolled28 locationsNCT00920972
Recruiting
Phase 2
MAGIC Ruxolitinib for aGVHD
Acute Graft Versus Host Diseaseadverse effectsAllogeneic Bone Marrow Transplantation
John Levine98 enrolled14 locationsNCT06936566
Recruiting
Phase 2
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
Acute Myeloid LeukemiaAMLMDS+4 more
Franziska Wachter37 enrolled2 locationsNCT05796570
Recruiting
Phase 2
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
AMLMDSHLH+6 more
Memorial Sloan Kettering Cancer Center31 enrolled1 locationNCT04644016
Recruiting
Phase 2
Orphan Indications for CD19 Redirected Autologous T Cells
Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALLInfants With Very High Risk KMT2A B-ALLPatients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation
Stephan Grupp MD PhD133 enrolled1 locationNCT04276870
Recruiting
Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaRecurrent High Risk Myelodysplastic Syndrome+4 more
M.D. Anderson Cancer Center63 enrolled3 locationsNCT03383575
Recruiting
Phase 2
Shingrix In Recipients of Allogeneic Transplants
Bone Marrow TransplantStem Cell Transplant
University of Colorado, Denver55 enrolled1 locationNCT05775718
Recruiting
Phase 2
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
Dyskeratosis CongenitaFanconi AnemiaMyelodysplastic Syndromes+5 more
Masonic Cancer Center, University of Minnesota48 enrolled1 locationNCT03579875
Recruiting
Phase 1Phase 2
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
HemoglobinopathiesBone Marrow Failure SyndromesMetabolic Disorders+3 more
Washington University School of Medicine29 enrolled4 locationsNCT03128996
Recruiting
Phase 2
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
Blasts More Than 5 Percent of Bone Marrow Nucleated CellsChronic Eosinophilic Leukemia-not Otherwise SpecifiedBCR-JAK2 Fusion Protein Expression+9 more
William Shomali10 enrolled4 locationsNCT03801434
Recruiting
Phase 1Phase 2
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Acute Myeloid LeukemiaHigh Risk Myelodysplastic SyndromeRecurrent Acute Myeloid Leukemia+5 more
M.D. Anderson Cancer Center80 enrolled1 locationNCT04047641
Recruiting
Phase 2
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
Juvenile Rheumatoid Arthritis (JRA)Primary Immunodeficiency (PID)Congenital Bone Marrow Failure Syndromes+4 more
Paul Szabolcs100 enrolled1 locationNCT01962415
Recruiting
Phase 2
Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures
Dyskeratosis CongenitaFanconi AnemiaBone Marrow Failure+7 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins27 enrolled1 locationNCT04232085
Recruiting
Phase 2
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
Acute Myeloid LeukemiaMyeloproliferative NeoplasmBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+4 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT03589729